Versant Ventures launches Cimeio Therapeutics with USD 50m Series A
13. April 2022 – Versant Ventures announced the debut of Cimeio Therapeutics, a biotechnology company developing a novel approach to cell therapies. Versant has made a USD 50m Series A commitment to Cimeio, which is the most recent start-up to emerge from the firm’s Ridgeline Discovery Engine in Basel, Switzerland.
Walder Wyss advises Versant Ventures in connection with the launch of Cimeio Therapeutics. The team includes Alexander Gutmans (Partner, Transaction/M&A & Venture Capital), Karina Tschon (Associate, Transaction/M&A & Venture Capital), Michelle Bruni (Senior Associate, Tax and Transaction/M&A), Lucas Maurer (Associate, Transaction/M&A & Venture Capital) and Bojan Momic (Associate, Employment).